The US Veterinary Healthcare market is expected to register a CAGR of around 5% during the forecast period, 2018 to 2023. Veterinary medicines are associated with treatment, diagnosis, and prevention of diseases among animals. It covers a variety of animal species, both, in domestic and wild.
Increasing Productivity at the Risk of Emerging Zoonosis
The growing meat consumption, especially for chicken and pork, is adding to the exposure of dangerous food-borne pathogens. The E. coli and Salmonella infections cause serious diseases among people, and can even be fatal at times, which is possible during the intensive production systems. Moreover, there is a risk of emerging new strains of influenza viruses, due to the long-distance transportation of animals. The farms are often in the same area, with a concentration of confined animals, which potentially enhances the risk of avian influenza transferring to pigs. The reassortment of the virus can lead to new strains and cause infections among humans. Further, these farms increase the risk of spreading and mixing of virus strains. Intensive farm practices are causing the risk of emergence of these bacteria in the food, as stressed animals become more susceptible to infection. The risk from zoonotic diseases is fuelling the market for United States veterinary healthcare. Inter-Governmental Organizations and the food production are making reforms to ensure health by the process of surveillance and vaccination, investing in R&D, and transfer with respect to vet health.
Additionally, advanced technology leading to innovations in animal healthcare is also a factor responsible for the growth of US veterinary healthcare market.
Increasing Costs of Animal Testing and Veterinary Services
Advances in veterinary care, over the past few years, have come at high price. For example, according to the North American Pet Insurance Association, a trade group, it is estimated that only 1-2% of the total United States pet population was insured by 2015-year end. Hence, very few are insured and the remaining pet owner population has to pay the amount from their own pockets. But, as the costs continue to increase, the United States has spent a record of USD 15.4 billion on vet services in 2015, up from the USD 8.6 billion in 2005. The increasing costs is the major concern and also, many diseases and injuries are diagnosed with an MRI, which used to be inaccessible to all except to the most well funded university hospitals. The MRI machines are available in many hospitals, and vets use this test as standard care for diagnosing and treating cancer, epilepsy, injury, etc, but the test itself costs over USD 1000, since MRI machines are incredibly useful and important diagnostic tools, the cost of test is out of reach for many pet owners, who would struggle to afford the surgery and/or treatment following the MRI, let alone the cost of the test itself. Thus, increasing cost of animal testing and veterinary services is hindering the growth of the market.
Also, lack of infrastructure and funding and use of counterfeit medicines are restraining the growth of veterinary healthcare market.
Vaccines to lead the Market
The Vaccines segment in United States veterinary healthcare market is expected to register a healthy CAGR during the forecasted period due to the presence of good healthcare infrastructure in the country, and it is also experiencing positive trends in the R&D developments.
Key Developments in the Market:
- June 2018: Elanco Animal Health introduced New Respiratory PRRS Vaccine a modified-live respiratory vaccine, which is effective in the reduction of porcine reproductive and respiratory syndrome (PRRS), respiratory form, in piglets two weeks or older
Major Players: Abaxis Inc., Bayer healthcare, Boehringer Ingelheim, Ceva Animal Health, Inc., Elanco (Eli lilly and company), IDVet, Merck Animal Health, Virbac Corporation, and Zoetis animal healthcare, amongst others.
Reasons to Purchase this Report
- Current and future US veterinary healthcare market outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
- This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Driver
6.1.1 Advanced Technology Leading to Innovations in Animal Healthcare
6.1.2 Increasing Productivity at the Risk of Emerging Zoonosis
6.2 Market Restraint
6.2.1 Lack of Infrastructure and Funding
6.2.2 Use of Counterfeit Medicines
6.2.3 Increasing Costs of Animal Testing And Veterinary Services
7. Market Segmentation
7.1 By Product Type
7.1.1 By Therapeutics
18.104.22.168 Medical Feed Additives
7.1.2 By Diagnostics
22.214.171.124 Immunodiagnostic Tests
126.96.36.199 Molecular diagnostics
188.8.131.52 Diagnostic Imaging
184.108.40.206 Clinical Chemistry
7.2 By Animal Type
7.2.1 Farm animal
7.2.2 Companion Animal
220.127.116.11 Dogs & Cats
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abaxis Inc.
9.2 Bayer healthcare
9.3 Boehringer Ingelheim
9.4 Ceva Animal Health, Inc.
9.5 Elanco (Elli lilly and company)
9.7 Merck Animal Health
9.8 Virbac Corporation
9.9 Zoetis animal healthcare
**List Not Exhausitive
10. Future of the Market